Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma

Conditions

• Anaplastic Lymphoma Kinase Positive Large B-Cell Lymphoma
• Refractory Plasmablastic Lymphoma
• Relapsed Plasmablastic Lymphoma

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Belantamab Mafodotin — DRUG
  Belantamab mafodotin will be administered intravenously at calculated dose on day 1 of each 21-day cycle.

Study Details

In this research study is looking to see how safe and effective belantamab mafodotin is in relapsed or refractory plasmablastic lymphoma or ALK+ large B-cell lymphoma. * This research study involves the study drug belantamab mafodotin. * Belantamab mafodotin is an antibody-drug conjugate (ADC), which is the combination of an antibody (a protein that binds to cells) and a drug. It works by using the antibody portion to enter into the lymphoma cells, and then releasing the drug portion to kill the lymphoma cells.

Key Dates

Start date

Jul 1, 2021

Status verified

Mar 2026

Primary completion

Nov 27, 2023

Completion

Nov 26, 2024

Study Design

Enrollment

10 participants (actual)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: (BELANTAMAB MAFODOTIN
  * Belantamab mafodotin will be administered intravenously on day 1 of a 21-day cycle. * Treatment is intended to be administered on an outpatient basis.

Primary Outcome Measure

Overall Response Rate [ Time Frame: Measured up to 2 years ]

Locations (3)

Find similar trials in Boston, MA